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A ccording to the CSHA, dementia affected over 252 600 of the Canadian population aged 65 years and older, with the prevalence of AD in that age group being 6% 1 in 1991. In 2000, another study by the CSHA estimated that there were 60 150 new cases of dementia every year. 2 The cost of caring for a patient with dementia includes direct and indirect medical costs, and expenditures are expected to grow rapidly with the increasing prevalence of dementia. Direct medical costs include hospitalization, physician visits, and medication, with institutionalization being the largest cost driver. 3 Indirect medical costs include home care by informal caregivers (such as family and friends), and loss of productivity by both the patient and the caregiver. The cost of caring for a patient aged 65 years and older with dementia, compared with a patient without dementia, was about 3 times higher (US$33 007) in a 2004 US study. 4 In 2005, direct and indirect medical costs were about US$148 billion in the United States, 5 where indirect costs accounted for US$36.5 billion (caregiver burden and loss of productivity).
In 1998, Hux et al, 6 extrapolating from CSHA data, found costs increased dramatically with increasing severity of AD. Institutionalization accounted for most of the costs in severe AD, when patients required total assistance with ADL. Since that study, the treatment for AD has changed, with the introduction of specific AD therapies: the cholinesterase inhibitors donepezil (1997), galantamine (2000) , and rivastigmine (2000) , and the N-methyl-D-aspartate antagonist, memantine, in 2004. 7 As these new treatment options are associated with acquisition costs, but may delay time to full-time care, 8, 9 changes in costs of caring for patients with dementia or AD in the community may result.
In the COSID, a 3-year prospective study of dementia patients in the community across Canada, investigators collected clinical, treatment, health status, and resource use data. 10 The objective of our study was to characterize the costs associated with changes in AD severity by using measures of cognition, function, and global staging.
Method

Canadian Outcomes Study in Dementia
COSID was a 3-year prospective, observational study that enrolled 903 subjects with dementia at 31 academic and community sites across Canada from 5 major regions: British Columbia, the Prairies, Ontario, Quebec, and the Atlantic provinces. Patients were enrolled and baseline measurements taken between August 2000 and March 2003. A detailed description of the methodology has been published previously. 10 The study was reviewed by local ethics boards for each site. Participants met the following inclusion criteria: aged 60 years and older; Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of dementia; community dwelling; and early or mild disease (GDS £ 5) at entry. Written informed consent was obtained from both the patient and the caregiver. Patients living in long-term care at the time of enrolment were excluded. Patient information, such as demographics, medical history, medications, neuroimaging, and specific diagnoses, was collected. Each patient and caregiver was interviewed at baseline and every 6 months over a total of 36 months. The dosage, unit, frequency, and dates of medications were collected. The patient's global (GDS), cognitive (3MS), and functional (SMAF) status were also recorded at baseline and every 6 months for 36 months. The GDS, a scale from 1 to 7 (no deficits to very severe stage of dementia), examines cognition, behaviours, and function 11, 12 and categorizes overall severity of illness. The SMAF measures functional ability in 5 areas: BADL, mobility, communication, mental functions, and IADL. 13 The 3MS is an extended version of the MMSE and MMSE scores can be derived from the 3MS. 14 Detailed resource use questionnaires were completed monthly by caregivers, with or without the assistance of the patient. Questions included duration and frequency of visits to a hospital, and frequency of community resource use such as home care nurses, Meals on Wheels, and respite care. In addition, data were collected regarding the patient or caregiver's loss of time from work or leisure activities as a result of the patient's dementia. This was used to determine time spent on informal caregiving and to estimate indirect costs. Questions were also asked regarding the caregiver's employment status, his or her relation to the patient, and the patient's level of prescription medication coverage. Direct costs were obtained from a detailed cost dictionary (compiled by surveying many service providers for each item). Medication costs were obtained from a British Columbia-based wholesale pharmacy 2000 price list. Indirect disease costs were calculated by determining the number of days the patient and (or) caregiver was prevented from performing their regular activities and determining the market value of the informal care provided in this time. This was estimated from Statistics Canada's 1997 domestic help hourly wage (adjusted for inflation) and was determined to be a unit cost of $102 daily. Direct medical costs included visits to a family doctor or 
Study Analysis
The analysis population we used included only those COSID subjects with a diagnosis of AD; subjects with other etiologies were excluded (for example, vascular dementia, mixed AD or vascular dementia, dementia with lewy bodies, and frontotemporal dementia) as small sample sizes in these categories precluded accurate cost estimates. Differential diagnoses were made using consensus papers or guidelines for each dementia type, as described previously. 10 The goal of the analysis was to characterize the demographic, clinical, and resource use data associated with AD at the baseline visit and then again later in the study when the subjects had progressed further in the disease. Because resource use data from the final study visit could be strongly influenced by the often sudden changes in resource use observed during the month preceding death or transition to a nursing home (2 of the more common reasons for discontinuation), rather than using data from the final study visit, baseline data were compared with data from the visit of interest. The visit of interest was defined as the second-to-last study visit (the preceding visit was used for subjects who did not provide resource use data at their second last visit).
Using the GDS, AD severity was grouped into the following categories: very mild (GDS = 2), mild (GDS = 3), moderate (GDS = 4), moderately severe (GDS = 5), or severe or very severe (GDS = 6). 12 For MMSE, similar to Hux et al, 6 AD severity was grouped into mild (MMSE = 21 to 26), mild to moderate (MMSE = 15 to 20), moderate (MMSE = 10 to 14), or severe (MMSE < 10). Similar to Small et al, 15 SMAF total scores were analyzed by quartiles, and disease severity was classified as high function (SMAF ³ -15), good function (SMAF < -15 but ³ -24), moderate function (SMAF < -24 but ³ -31.5), or low function (SMAF < -31.5). Changes in severity from baseline to the visit of interest were assessed for the GDS and MMSE by examining the change in the proportion of subjects who were found to be either moderately severe or worse between the baseline visit and the visit of interest using McNemar's test. Paired t tests were used to examine the changes in mean SMAF scores (SMAF-Total, SMAF-BADL, and SMAF-IADL).
The base-10 logarithm was taken of each total cost value, and the association between the severity scores and the log10-transformed total costs at the visit of interest were analyzed both categorically, using ANOVA to compare costs across disease severity groups, and numerically, using linear regression of the (log10-transformed) total costs on the severity scores. The log-transformed costs were used in the regression models to ensure more normally distributed residuals as well as more homogeneous variances, as is often necessary when analysing cost data (that is, to better satisfy the assumptions of the statistical method used). Backward elimination regression analysis was used to achieve a parsimonious multiple regression model for costs combining the severity scores and a set of covariates (including age, sex, education level, primary residence, and behavioural disturbances as measured by the NPI). The backward elimination analysis started with all predictors and sequentially eliminated those with P > 0.2. This regression analysis was first performed incorporating SMAF-Total, and was then repeated using the 2 component scores, SMAF-BADL and SMAF-IADL. Standardized regression coefficients have also been calculated to permit the comparison of the numerical effects of each score despite the differences in numerical scales used. The standardized regression coefficients have been calculated after dividing the severity score by its interquartile range and can be interpreted as a standardized effect of the severity score, which is the difference between a subject with a standard low severity score compared with the same subject with a standard high severity score (specifically, the difference between the 25th compared with the 75th percentiles of the severity score). The arbitrary numerical scale of each severity score is thus removed, facilitating comparison between the effect of each severity score on total cost. The estimated effect was calculated as the anti-log10 of the standardized regression coefficient to provide a direct representation of the numerical effect of each predictor on actual, nontransformed cost.
Results
In total, 559 of the 731 (77%) subjects in COSID who were diagnosed with AD could be included in the analysis population. The remainder were excluded owing to missing resource use data. Among those included, 57.2% were female, 97.9% were Caucasian, mean age at baseline was 76.4 years (SD 6.4), 67.1% were married, and 83.7% lived in their own home. Baseline characteristics for the entire COSID population have been reported previously. 10 Time from baseline to the visit of interest ranged from 5 to 30 months, with a median of 1 year.
Scores from the baseline and visit of interest are summarized in Table 1 for the MMSE, GDS, SMAF-Total, SMAF-BADL, and SMAF-IADL. From baseline to visit of interest, all severity scores showed increased severity, with more subjects categorized as moderately severe or worse by the GDS and MMSE at the visit of interest; as well, mean scores worsened significantly for SMAF-Total, SMAF-BADL, and SMAF-IADL (all P < 0.001). Figure 1 shows the total monthly cost of AD when patients were grouped by disease severity at the visit of interest as measured by the GDS, MMSE, and SMAF, respectively.
Significantly higher total costs were associated with greater disease severity for each severity measure (P < 0.001, ANOVA). Measured by the GDS, in the very mild disease stage, the mean monthly cost of caring for a subject was $367, with most costs associated with medication. For all other severity levels, most of the costs were attributed to indirect costs. The mean monthly cost of caring for a subject in the severe or very severe disease stage was $4063. Measured by the MMSE, in the mild disease stage, the mean monthly cost of caring for a subject was $1386 per month, with most costs attributed to indirect costs compared with $3244 per month for a severe subject, with most costs still attributed to indirect costs.
Additionally, longitudinal data were examined to assess the effect of disease severity on change in costs from baseline to visit of interest. Figure 2 demonstrates that there was a greater increase in cost of care over time for patients in the severe disease stage compared with patients that were in the milder stages of the disease at the visit of interest.
Regression models were used to examine the relation between disease severity and cost of care in more detail. Each severity measure has a highly significant positive association with total costs, with increased severity corresponding to increased costs (all Ps < 0.001). GDS, MMSE, and SMAF-BADL have similar effects corresponding to an approximate doubling (or more) of costs. Patients at the 75th percentile of GDS scores had costs at about 192.9% of the costs for patients at the 25th percentile, while patients with high scores on the MMSE and SMAF-BADL had costs at 57.5% and 45.5%, respectively of costs for patients at low scores. SMAF-Total and SMAF-IADL have numerically stronger influences, with patients at the 75th percentile of each scale having estimated costs that are one-third (35.7%) of costs for patients at the 25th percentile.
In the context of multiple regression where the joint effects of the severity scores and the covariates can be examined, the subject's sex and NPI scores both have highly significant effects on total costs (both Ps < 0.001) (data not shown).
Female subjects have total costs that are about 86% higher than those of male subjects, and higher NPI scores add about 33% to costs. Worse SMAF-BADL scores account for an additional 84% (P = 0.01) and worse SMAF-IADL account for an additional 48% (P < 0.001) increase in total costs. After controlling for the other predictors, the effect of GDS was not significant (P = 0.05). Age, sex, education level, primary residence, and MMSE were removed during backward 
Discussion
AD patients' monthly costs were strongly and positively associated with the severity of the disease as measured by cognitive, global, and functional assessments. The cost of treating a patient with very mild AD was $4406 per year, while the cost of treating a patient with severe or very severe AD was $48 752 per year in the community in Can$, in 2000. Independent predictors of total costs were: being female, having poorer function, and more neuropsychiatric symptoms. Previous studies have found similar cost predictors with female sex 16 as well as with poorer function and more severe neuropsychiatric symptoms. 6, 15, 16 Among the 3 severity scores examined, only the SMAF, but neither the MMSE nor the GDS, were independently associated with a change in costs. This agrees with the results from a British study by Wolstenholme et al 17 that demonstrated that loss of ADL had a greater impact on costs than loss of cognition in patients with dementia. Similarly, a US study 15 showed that total cost of care increased with decreasing function as measured by numerous rating scales. However, that study looked at disease severity only as measured by IADL and physical functioning and not by cognition.
Our results suggest that the largest contributor to the total cost burden for a person living in the community with AD is indirect costs for all but very mild disease severity. These results are similar to those of Small et al, 15 a US study that found increased resource use (direct and indirect costs) with disease severity in community patients with AD. They also demonstrated that indirect costs are the largest component of the cost of caring for a patient with AD. However, when institutionalized patients were included, Hux et al 6 demonstrated that the largest contributor to costs were indirect costs in the mild disease stage and institutionalization in severe disease stage patients. The large contribution of indirect costs across levels of disease severity highlights the importance of including the societal perspective (that is, loss of productivity) when conducting economic evaluations in this particular population. Our study also incorporated the longitudinal data from the COSID study, and looked at changes in cost over time regarding disease severity. Results demonstrated that, over time, changes in cost from baseline were greatest in more severe patients, compared with patients who remained mild. This demonstrated that the relation between costs and disease severity persisted over time, suggesting that as a patient deteriorated, costs increased.
These results are similar to those of Hux et al, 6 6 Their study used survey data from the CSHA to estimate the cost of caring for a person with AD based on disease severity, but did not collect actual resource use. Also, while Hux et al 6 included patients who were institutionalized, the COSID focused exclusively on patients living in the community. Finally, besides the MMSE, our study also looked at disease severity as measured by the GDS and the SMAF, which were not available from the CSHA. Cognition as a sole outcome has been criticized in clinical trials and pharmacoeconomic analyses 18, 19 and functional level may be a better predictor of cost of care. 17, 20 There are some limitations to this analysis. First, the COSID population did not include patients who were institutionalized, and thus conclusions can only be drawn for communitydwelling patients with AD. If institutionalized patients were included in our study, monthly direct costs could be expected to be much higher, estimated to be $3800 to $4800 monthly. 9, 21 This analysis has compared resource use at 2 single time points (baseline and visit of interest), and because resource use is highly variable between time points, rare events may bias the results. However, given the large sample size, we believe that the extra variability, owing to using resource use data from a single time point, has been mitigated. Another limitation was reliance upon a caregiver survey for resource use data rather than direct measurement.
Conclusions
The cost of caring for a patient with AD is strongly associated with disease severity, as measured by changes in cognition and function. Those in the most severe stages of the disease experienced the greatest change in cost from the baseline visit to the visit of interest, with function driving costs. Even in a cohort of patients not institutionalized, the relation between severity and cost is strong. Therefore, any interventions that slow down the progression of AD can potentially reduce costs from the payer and the societal perspective. However, this remains to be convincingly and rigorously demonstrated.
